REVVITY, INC.

Life Sciences

Revenue for the three months ended July 5, 2026 was $358.7 million, as compared to $365.9 million for the three months ended June 29, 2025, a decrease of $7.2 million, or 2%. The decrease in our Life Sciences segment revenue during the three months ended July 5, 2026 was driven by a decrease of $10.2 million in Software revenue, partially offset by an increase of $3.0 million in Life Sciences Solutions revenue.

Revenue for the six months ended July 5, 2026 was $720.5 million, as compared to $706.3 million for the six months ended June 29, 2025, an increase of $14.3 million, or 2%. The increase in our Life Sciences segment revenue during the six months ended July 5, 2026 was driven by an increase of $16.5 million in Life Sciences Solutions revenue, partially offset by a decrease of $2.3 million in Software revenue. Our Life Sciences segment benefited from an extra fiscal week for the six months ended July 5, 2026.

Segment operating income for the three months ended July 5, 2026 was $111.5 million, as compared to $115.5 million for the three months ended June 29, 2025, a decrease of $3.9 million, or 3%. Segment operating margin decreased 50 basis points in the three months ended July 5, 2026, as compared to the three months ended June 29, 2025, primarily due to strategic investments in software and new product development, partially offset by favorable product mix shift.

Segment operating income for the six months ended July 5, 2026 was $215.5 million, as compared to $221.2 million for the six months ended June 29, 2025, a decrease of $5.7 million, or 3%. Segment operating margin decreased 150 basis points in the six months ended July 5, 2026, as compared to the six months ended June 29, 2025, primarily due to strategic investments in software and new product development and impact of the extra fiscal week in the six months ended July 5, 2026.

Diagnostics

Revenue for the three months ended July 5, 2026 was $371.0 million, as compared to $354.4 million for the three months ended June 29, 2025, an increase of $16.6 million, or 5%. Theincrease in our Diagnostics segment revenue duringthe three months ended July 5, 2026 was driven by an increase of $20.7 million in Reproductive Health revenue, partially offset by a decrease of $4.1 million in Immunodiagnostics revenue.

Revenue for the six months ended July 5, 2026 was $720.3 million, as compared to $678.8 million for the six months ended June 29, 2025, an increase of $41.5 million, or 6%. Theincrease in our Diagnostics segment revenue duringthe six months ended July 5, 2026 was driven by an increase of $41.3 million in Reproductive Health revenue and an increase of $0.2 million in Immunodiagnostics revenue. Our Diagnostics segment benefited from an extra fiscal week in the six months ended July 5, 2026.

Segment operating incomefor the three months ended July 5, 2026 was $112.9 million, as compared to $89.4 millionfor the three months ended June 29, 2025, an increase of $23.4 million, or 26%. Segment operating margin increased 520 basis points in the three months ended July 5, 2026, as compared to the three months ended June 29, 2025, primarily due to tariff refunds and cost containment initiatives.

Segment operating incomefor the six months ended July 5, 2026 was $189.0 million, as compared to $163.4 millionfor the six months ended June 29, 2025, an increase of $25.6 million, or 16%. Segment operating margin increased 220 basis points in the six months ended July 5, 2026, as compared to the six months ended June 29, 2025, primarily due to tariff refunds and cost containment initiatives, partially offset by product mix shift and the impact of the extra fiscal week in the six months ended July 5, 2026.